Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 versus concurrent indacaterol plus glycopyrronium in moderate to severe COPD
2011-006050-91Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of indacaterol + glycopyrronium, indacaterol and glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Trough forced expiratory volume in 1 second (FEV1) after 28 days of blinded treatment. Started Feb 2012; status: completed.
02
Drugs
indacaterol + glycopyrroniumindacaterolglycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-006050-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006050-91.